Japan’s Astellas Pharma acquires US biotech firm Universal Cells for $102.5m Visual from Astellas' website Mars Woo February 14, 2018 PremiumTokyo-listed Astellas Pharma has acquired US-based biotech firm Universal Cells Inc. for up to $102.5 million, giving the Japanese firm access to the latter’s proprietary technology. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Should your colleagues be reading this article too? Contact us for corporate subscriptions at firstname.lastname@example.org.